In my humble opinion, fair value a year ago was 35 to 45 cents, due to high percentage terms of 70% success rate after tax data confirmation and IND submission in human trials.Take away geopolitical developments, rate increases and inflation, that price would have to be adjusted to 25 to 35/ cents.
In case of a licence deal for PMS, kidney, glaucoma, a price appreciation is dependent on the advance pay which I would target at 60 mil, adding 25 cents to the share price minus dilution of 25% share issuance to partner, leaving us at around 50 cents. After inflation coming down during 23 and recessions fully priced in, a forward looking market would again appreciate the pipeline outlook of the stock and share could finish the year 23 at around 65 cents.
Interim results for first ocular human trials would potentially be a game changer freeing additional ,milestone payments for more programs in the pipeline. End of 23 could mark the onset of Instos starting to buy in and an entirely new price level for 24, all IMO
PYC Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)